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The year 2007 marks the 10th anniversary of the approval
of letrozole (Femara
1) in the United States, while 2006
marked not only the 10-year milestone of letrozole’s
approval in Europe but also the 25th anniversary of
Novartis’s (then Ciba-Geigy [1970–1996]) dedication to
the aromatase inhibitor (AI) program. It began with the
introduction of the ﬁrst-generation AI aminoglutethimide
(Orimeten
1) in 1981, progressed to the marketing of the
steroidal AI formestane (Lentaron
1), development of the
second-generation AI fadrozole (Afema
1), and ﬁnally led
to letrozole, the most recent third-generation agent. This
long track record in the development of AIs is unique in the
pharmaceutical industry.
It is quite rare to be involved in the development of a
drug that successfully completes the journey from discov-
ery to approval and then advances care in a therapeutic
ﬁeld. The investigators involved in the early development
of letrozole had such an opportunity.
At Ciba-Geigy (later Novartis), as in other pharmaceu-
tical companies, thousands of compounds would be
synthesized each year and, on average, only one or two
would reach clinical development. In 1983–1984, the
center of excellence for cancer research was transferred
from the United States to Basel, Switzerland. As the newly
appointed deputy head of the endocrine research depart-
ment at Ciba-Geigy, I was assigned the AI project because
of my previous experience and expertise in endocrine
projects with possible oncology indications. As part of the
completion of the transfer of all oncology activities to
Basel, the last batch of compounds synthesized by Dr.
Robert Bowman arrived in Basel from the United States.
Unknown to us, the compound that would become known
as letrozole was among them. At this point in time, the
second-generation AI fadrozole was undergoing clinical
testing and was thus our lead compound, with all attention
focused on it. The newly arrived compounds were stored in
a freezer until an effective and robust in vivo assay was
available. In 1986, when such an assay was developed in
our labs, these last compounds were ﬁnally tested. The
results of our early experiments showed that one compound
appeared to be different from any of the others we had
tested, in that it had a profound effect on the rat uterus.
Considering that in those early days, compounds were
screened at low mg/kg doses and that aminoglutethimide
was active at about 100 mg/kg, we were very surprised to
ﬁnd that even at doses as low as a few hundred lg/kg, the
new compound reduced the uterus to a very hair-like ﬁne
structure. It was at doses as low as 1 lg/kg that we saw
dose-dependency in reducing uterine weight. This made
our new compound inﬁnitely more potent than any other AI
previously tested.
Following this exciting preclinical discovery, and the
subsequent preclinical proﬁling of letrozole as the most
potent and selective AI tested, a brainstorming meeting was
held to discuss the design of potential future clinical trials.
Prof. Henning T. Mouridsen, one of the early investigators,
speculated that this compound, now known as letrozole,
showed great promise in revolutionizing breast cancer care.
The letrozole program beneﬁted tremendously in that it
was not developed sequentially but rather dynamically, as a
result of many discussions among all members of the
letrozole team. Many protocol design meetings were
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DOI 10.1007/s10549-007-9699-0held, and the input of outside physicians was carefully
considered. Dr. Patrick Trunet, a Novartis clinician and the
ﬁrst International Project Team Leader for letrozole, was
involved in the trial design, and he selected several external
physicians he had previously worked with, including Prof.
Mouridsen, his personal clinical experiment advisor. Other
physicians involved in the clinical trial design included
Drs. Richard Santen, James Ingle, Allan Lipton, Mitch
Dowsett, and Ian Smith.
The enthusiasm over letrozole’s potential grew even
more following the completion of a successful in-house
phase 1 study in healthy male volunteers, which used a
letrozole solution instead of tablets in order to speed up the
development process [1]. Due to the promising preclinical
and phase 1 results, and once again to shorten development
time, a novel phase 3 trial was designed using an innova-
tive three-arm combined phase 2B/3A design, which tested
2 doses of letrozole against each other and against a
comparator. Mrs. Hilary Chaudri Ross, the team statisti-
cian, helped formulate the phase 2/3 study design and kept
us on course throughout the clinical development process.
Mrs. Chaudri Ross was also intimately involved in other
aspects of trial design, including decisions regarding end
points and powering, and thus became the project statisti-
cian for all our AI trials and a core member of the project
team. Her extensive involvement in the design of the
clinical trial set a precedent for statisticians to be repre-
sented on all project teams, which is now standard at
Novartis.
One of the important advantages of this novel trial
design was that we were able to obtain results much faster
than with the traditional phase 3 trial design. Our results
showed that 2.5 mg of letrozole was signiﬁcantly more
efﬁcacious than the 0.5-mg dose, and more importantly,
that 2.5 mg was signiﬁcantly better than the comparator.
The potency of letrozole was further demonstrated in a
small experimental calibration trial in the ﬁrst-line setting,
where for the ﬁrst time it appeared that letrozole might
even be superior to tamoxifen. This ﬁnding allowed us to
design a phase 3 trial, the Femara P025 study, which was
powered to show the superiority rather than equivalence
of letrozole over tamoxifen [2]. In addition, the P025
letrozole study had a unique crossover design. At an FDA
advisory meeting, Novartis was complimented on having
included a signiﬁcant proportion of elderly women in
trials and on involving three independent geographical
areas (Europe, North America, and the rest of the world)
in the P025 study, resulting in area-speciﬁc, reproducible
results.
It is important to remember that letrozole was developed
with one medical scientiﬁc concept in mind–that maximum
estrogen suppression would lead to maximum tumor sup-
pression. From the very beginning, we reasoned that by
using the maximum tolerated dose of letrozole with max-
imum estrogen suppression, the stimulus for the hormone-
sensitive breast cancer can be most efﬁciently suppressed.
Thus, efﬁcacy was the most important aim, and the team
believed that we were in the process of developing the most
potent compound.
The team, led by Dr. Trunet, pushed from translational
research to registration with extensive discussions on the
concept of maximum estrogen suppression, new innovative
clinical trial design, and long-term (10-year) strategy. It
was one of the ﬁrst projects within Ciba-Geigy/Novartis
where Clinical and Research (and other line functions such
as Drug Regulatory Affairs, Drug Metabolism and
Pharmacokinetics, Toxicology, and Pharmaceuticals
Development) worked together very closely. In addition,
the same team was involved from research to market,
which was one of the key success factors.
Subsequent endocrine proﬁling in humans showed that
letrozole was an extremely powerful inhibitor of aroma-
tase; and this, along with our conviction and belief in the
compound, led to the fast-tracking of the letrozole clinical
program within Novartis and to the subsequent launch of
the drug. The ﬁrst registration of letrozole for breast cancer
was in France in mid 1996, and also in 1996, the drug was
approved for the treatment of advanced breast cancer in
Europe, with approval in the United States occurring 1 year
later. It was ﬁrst launched as ﬁrst-line treatment for
advanced breast cancer and for the neoadjuvant setting in
the United Kingdom in 2001. Following the advanced
breast cancer indication, letrozole received approvals in the
extended adjuvant and most recently in the early adjuvant
setting [3].
At the time letrozole was discovered, the general con-
sensus in the medical community was that endocrine
therapy with tamoxifen (Nolvadex
1) was the highest
achievable standard of care for postmenopausal women
with early breast cancer. The discovery and development of
new agents such as letrozole was, therefore, met with early
skepticism in the medical community; but the power of our
results was convincing enough to accelerate the clinical
trials needed to show that we were indeed dealing with a
possibly new paradigm in the treatment of breast cancer.
All of the researchers involved in the development of
letrozole were excited by the recognition that AIs repre-
sented an entirely new class of drugs with mechanisms of
action different from those of tamoxifen and a different
side-effect proﬁle. The highly successful interaction and
mutual respect between Novartis and external investigators
was key to the rapid development of letrozole. Further-
more, the third-generation AI program established the
concept of large, randomized trials. These large adjuvant
studies sponsored by the pharmaceutical industry and
guided by the scientiﬁc expertise of external investigators
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greatly improved the quality of the data obtained in clinical
studies.
Prior to the discovery of letrozole, many of us had a long
history of conducting adjuvant endocrine trials. Interest-
ingly, one of the ﬁrst adjuvant endocrine studies, which
compared tamoxifen with diethylstilbestrol (estrogen)
versus control treatment, was run by Dr. Mouridsen [4]. In
contrast with today’s endocrine therapies, which involve
complete estrogen inhibition, this study as well as other
studies at the time supported the use of high-dose estrogen
as standard endocrine therapy in postmenopausal women.
Although estrogen therapy did show clinical efﬁcacy, the
treatment was toxic, with serious adverse events. Thus,
paradoxically, the endocrine adjuvant treatment paradigm
has evolved from estrogen administration to complete
estrogen inhibition with the most potent class of drugs, the
AIs.
It is unusual for a drug to be approved globally for
multiple indications. Due to its efﬁcacy and approval in all
treatment settings, there is no doubt that letrozole will
continue to contribute to advances in breast cancer care.
After having looked back at the early days in the devel-
opment of letrozole, it would be appropriate that we cast a
glance into what the future might bring. One of the next
exciting programs for AIs is combining them with signal
transduction inhibitors. Since it is possible to block the
estrogen receptor pathway almost completely with letro-
zole, the next step should be to target those growth
pathways that may be up-regulated by complete blockade
of the estrogen-dependent pathways. Thus, several studies
investigating the efﬁcacy of letrozole in combination with
targeted therapies such as RAD001 [5], bevacizumab [6],
or trastuzumab [7] are under way. Furthermore, emerging
clinical data indicate that adjuvant letrozole therapy might
be particularly effective in reducing the early risk of distant
metastases, a well-recognized cause of breast cancer death
[8, 9]. The outstanding efﬁcacy of letrozole in preventing
distant recurrences suggests that letrozole is the optimal AI
to give in the initial adjuvant setting, because early distant
relapse prevention with letrozole should translate into
improved overall survival. Future studies will provide
additional insight into the full spectrum of the beneﬁts of
letrozole. What is clear from the data obtained over the last
decade is that the full letrozole story is still unfolding.
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